MedPath

PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.

Not Applicable
Completed
Conditions
Myelodysplastic Syndromes
Interventions
Other: research of disease-related factors
Other: research of comorbidities
Other: physical performance
Registration Number
NCT02689622
Lead Sponsor
University Hospital, Toulouse
Brief Summary

No prospective study was conducted in elderly patients with cancer to assess the relative value of disease-related and patient-related prognosis factors. Patient-related prognostic factors have been highlighted in elderly patients with cancer resulting in the necessity of a geriatric assessment. The impact on overall survival of all of these factors was recognized in elderly people with cancer but remains unknown in High Risk Myelodysplastic Syndromes (HR-MDS). Therefore this information could be crucial to better select geriatric assessment domains relevant for the prediction and to recommend simplified tool after stratification of geriatric assessment domains thanks to their predictive value.

The main hypothesis is that patient-related factors will have a better capacity to predict survival and treatment tolerance than disease-related factors in HR-MDS aged 75 and over and that the predictive value will be different among assessment tools which allows a selection of reduced number of tools for clinical use.

To best knowledge estimation of predictive value of geriatric assessment tools remains unknown and explains why no standardization of practice exists. In testing all tools at the same cohort of patients allows to compare different tools and to define minimal and optimal geriatric assessment for HR-MDS. To determine the best strategy of geriatric assessment will allow in a second time to measure the impact of the use of this geriatric standardized evaluation by comparing patients'care and prognosis according to the use or not by the doctors of the new scores.

Research outcomes are various medical, economic and ethic. Medical because decision-making will be improved with simplified geriatric assessment; economic because a better knowledge of geriatric assessment will improve treatment toxicity prevention and decrease treatment costs. Ethic will be associated with this project because a better knowledge of geriatric assessment tools to predict survival and tolerance treatment could improve the choice of best supportive care if prognosis markers are not favorable to active therapy. This project could induce important modification of practice in this area to an improved personalized treatment and simplification of geriatric assessment allowing a large diffusion in hospitals and clinics.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
157
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Evaluation of disease prognostic factorsresearch of disease-related factorsResearch of disease-related factors, research of comorbidities, geriatric assessment (Mini Mental Status Examination (MMSE), Geriatric Depression Scale-15, Mini Nutritional Assessment, Short Physical Performance Battery, grip strength, Fried criteria, Activities of Daily Living (ADL), Instrumental-ADL, G8, self-reported health status, quality of life Quality of Life Questionnaire-C30, Elderly Cancer Patients-14, EQ5D) at inclusion. At 3 months ADL and physical performance. Grade 3/4 toxicities and serious adverse events will be assessed during 6 months after inclusion (using NCI-COMMON TERMINOLOGY CRITERIA version 2.0) whatever treatment type (chemotherapy, supportive care).
Evaluation of disease prognostic factorsresearch of comorbiditiesResearch of disease-related factors, research of comorbidities, geriatric assessment (Mini Mental Status Examination (MMSE), Geriatric Depression Scale-15, Mini Nutritional Assessment, Short Physical Performance Battery, grip strength, Fried criteria, Activities of Daily Living (ADL), Instrumental-ADL, G8, self-reported health status, quality of life Quality of Life Questionnaire-C30, Elderly Cancer Patients-14, EQ5D) at inclusion. At 3 months ADL and physical performance. Grade 3/4 toxicities and serious adverse events will be assessed during 6 months after inclusion (using NCI-COMMON TERMINOLOGY CRITERIA version 2.0) whatever treatment type (chemotherapy, supportive care).
Evaluation of disease prognostic factorsphysical performanceResearch of disease-related factors, research of comorbidities, geriatric assessment (Mini Mental Status Examination (MMSE), Geriatric Depression Scale-15, Mini Nutritional Assessment, Short Physical Performance Battery, grip strength, Fried criteria, Activities of Daily Living (ADL), Instrumental-ADL, G8, self-reported health status, quality of life Quality of Life Questionnaire-C30, Elderly Cancer Patients-14, EQ5D) at inclusion. At 3 months ADL and physical performance. Grade 3/4 toxicities and serious adverse events will be assessed during 6 months after inclusion (using NCI-COMMON TERMINOLOGY CRITERIA version 2.0) whatever treatment type (chemotherapy, supportive care).
Primary Outcome Measures
NameTimeMethod
IPPS score1 year
Secondary Outcome Measures
NameTimeMethod
percentage of patients who had adverse events grade 3 or higher or having a serious adverse event6 months
difference of geriatric assessment score between day 1 and 3 monthday 1 and 3 months

Trial Locations

Locations (31)

Hôpital Sud

🇫🇷

Amiens, France

CH Henri Duffaut

🇫🇷

Avignon, France

CH Boulogne sur mer

🇫🇷

Boulogne Sur Mer, France

CHU Albert Michallon

🇫🇷

Grenoble, France

CH de Lens

🇫🇷

Lens, France

CHU Limoges

🇫🇷

Limoges, France

CH Versailles

🇫🇷

Le Chesnay, France

Hôpital COCHIN

🇫🇷

Paris, France

Hôpital de l'archet I

🇫🇷

Nice, France

Chu Brabois

🇫🇷

Nancy, France

Ch Lyon Sud

🇫🇷

Lyon, France

Institut Paoli Calmette

🇫🇷

Marseille, France

Hôpital St Louis

🇫🇷

Paris, France

Centre Henri Becquerel

🇫🇷

Rouen, France

CH St Malo

🇫🇷

Saint Malo, France

CH du Mans

🇫🇷

Le Mans, France

CHU Henri Mondor

🇫🇷

Creteil, France

Chu Angers

🇫🇷

Angers, France

CH Sud Francillien

🇫🇷

Corbeil Essonnes, France

Hôpital saint vincent de paul - Institut Catholique

🇫🇷

Lille, France

CH de Meaux

🇫🇷

Meaux, France

Chu Hotel Dieu

🇫🇷

Nantes, France

CH Saint Jean

🇫🇷

Perpignan, France

Hôpital Bretonneau

🇫🇷

Tours, France

CHU Toulouse

🇫🇷

Toulouse, France

CH Annecy

🇫🇷

Annecy, France

CH Blois

🇫🇷

Blois, France

CHU Poitiers

🇫🇷

Poitiers, France

Hôpital Pontchaillou

🇫🇷

Rennes, France

CH René Dubos

🇫🇷

Pontoise, France

CH Princesse Grâce

🇲🇨

Monaco, Monaco

© Copyright 2025. All Rights Reserved by MedPath